Monday, May 18, 2026

Latest

Allied Gold Books $58.3M Q1 Loss, Adjusted Earnings Hit $48.6M Ahead of Zijin Takeover

Ethics Filing Reveals President Bought AI Chip, Defense Stocks Days Before Favorable Administration Decisions

200 Jets, Not 500: Boeing’s China Deal Disappoints Wall Street

Saudi Arabia Is Building a Post-War Middle East Security Pact, and the US and Israel Aren’t in It

Africa CDC Signals Alert On Ebola Outbreak In DRC; Deaths At 65

Amazon Cuts More Jobs in Seller Services as Tech Layoffs Surpass 45,000

The Iran War’s Hidden Bill: 30-Year Treasury Yields Hit 5% for the First Time Since 2007

After Denying, Gautam Adani Moves To Settle $175M SEC Fraud Case With $6M Payout

Sanders, Ocasio-Cortez Push For A Hold On America’s AI Buildout

Sheinbaum Confirms Pemex CEO Departure, Names Carpio as Successor

Revive Therapeutics

Revive Sees Expanded Access Protocol Approved For Compassionate Use Of Bucillamine

September 16, 2020, 08:23:03 AM

Revive Therapeutics To Conduct Phase 1 Clinical Trials For Psilocybin

September 2, 2020, 08:43:51 AM

Revive Receives Approval From Independent Review Board For Phase Three Study

August 31, 2020, 08:56:26 AM

Revive Submits for IRB Approval; Expects to Enroll Patients in September

August 26, 2020, 10:07:43 AM

Revive Expands Phase 3 COVID-19 Study To Asia Pacific Region, Canada

August 19, 2020, 12:34:40 PM

Revive Therapeutics Signs MOU With Attwill Medical, Manufacturer For Vaxart, For Phase 3 Clinical Trials

August 14, 2020, 08:50:35 AM

Revive Therapeutics Receives First Prototype of Orally Dissolvable Psilocybin Film Strips

August 11, 2020, 08:53:42 AM

Revive Announces Timeline For Phase 3 Studies, Sees Beneficial Psilocybin Developments

August 5, 2020, 09:50:58 AM

Three Things to Know About ‘Phase 3 COVID Player’: Revive Therapeutics

August 3, 2020, 10:11:55 AM

Revive Therapeutics Granted FDA Approval For Phase 3 Clinical Trial For Bucillamine In COVID-19 Treatment

July 31, 2020, 09:16:29 AM

Latest News

Russia Hit a Chinese Ship One Night Before Putin’s Beijing Summit

SpaceX’s Prospectus Is Coming—and the Hype Is Already Ahead of the Numbers

Starbucks Cuts 300 Corporate Jobs and Closes Four Regional Offices

Canada Confirms First Hantavirus Case Linked to MV Hondius Cruise Ship Outbreak

Crypto Market Takes Another Hit as Bitcoin Dips Below $77K in Monday Flash Crash

Barakah Nuclear Plant Takes First Hit of Iran Conflict, Forcing Reactor to Backup Power

First Majestic Q1 Earnings: A Bang Up Quarter

Copper’s Structural Shortage May Be Here to Stay | Colin Joudrie – Selkirk Copper

Why Barrick’s “Strong” Quarter Wasn’t So Strong | Q1 2026 Earnings

Why Copper Could Be Heading to a Price No One Is Ready For | Craig Parry – Vizsla Copper

Video Articles

First Majestic Q1 Earnings: A Bang Up Quarter

Copper’s Structural Shortage May Be Here to Stay | Colin Joudrie – Selkirk Copper

Why Barrick’s “Strong” Quarter Wasn’t So Strong | Q1 2026 Earnings

Recommended

Canada Confirms First Hantavirus Case Linked to MV Hondius Cruise Ship Outbreak

Altamira Gold Extends Maria Bonita Porphyry System Westward With 70.6 Metres At 0.51 g/t Hit

Trending

Welcome to The Deep Dive, where we focus on providing investors of Canadian junior stock markets the knowledge they need to make smart investment decisions. We take a closer look at all data relating to organizations to create quality stock analysis for investors. Not a recommendation to buy or sell securities. Always do additional research and consult a professional before purchasing a security.